1. [Myeloproliferative disorders "Philadelphia negative" and JAK2V617F mutation: study of 15 cases in Togo].
- Author
-
Padaro E, Agbetiafa K, Delagnon Kueviakoe IM, Layibo Y, Amegbor K, Vovor A, Giraudier S, Sanogo I, and Segbena AY
- Subjects
- Adult, Aged, Amino Acid Substitution physiology, Cohort Studies, Female, Humans, Longitudinal Studies, Male, Middle Aged, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders epidemiology, Phenylalanine genetics, Prognosis, Togo epidemiology, Valine genetics, Janus Kinase 2 genetics, Mutation, Missense physiology, Myeloproliferative Disorders genetics, Philadelphia Chromosome
- Abstract
The goal of our study is to document the prevalence of change JAK2V617F among patients reached of myeloproliferative syndromes (MPS) in Togo in order to evaluate frequencies. This descriptive study included 15 patients followed with the CHU Campus for a SMP. The research of JAK2 change by PCR was carried out with the APHP Henri Mondor of Creteil (France). During the study period, 15 patients followed for MPS (9 cases of polycythemia Vera, 5 cases of essential thrombocytemia and a case of primitive myelofibrosis) profited from the research of JAK2 change. The Middle age of the patients was respectively of 45±18 years; of 55±6 years for the PV and the essential thrombocytemia. The patient followed for primitive myelofibrosis was 72 years old. Sex-ratio (H/F) was of 2. JAK2 Change was positive in 5 cases out of 9 (55.5%) of the polycythemia Vera, at 3 patients out of 5 (60%) followed for essential thrombocytemia but negative for patient reached of primitive myelofibrosis. In conclusion, JAK2 Change has an interest diagnosis and forecast in the MPS negative Chromosom Philadelphia and can be systematic even in Africa Sub-saharian.
- Published
- 2012
- Full Text
- View/download PDF